



## Abivax releases the results of its June 5, 2023 ordinary and extraordinary general meeting

June 6, 2023

- **Shareholders approved all proposed resolutions**

**PARIS, France, June 6, 2023 – 6:00 p.m. (CEST)** – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, held its ordinary and extraordinary general meeting of shareholders on June 5, 2023, which was chaired by Marc de Garidel, CEO of Abivax and interim Chairman of the Board of Directors.

The shareholders have adopted all the resolutions approved by the Board of Directors and, in particular, the financial statements for the 2022 financial year, the compensation policy applicable to the Chairman, the Chief Executive Officer and the directors, as well as delegations granted to the Board of Directors related to financial transactions.

Shareholders also ratified the cooptation of Mr. Marc de Garidel as Board member and approved the appointment of Agili(3f) as co-statutory auditors for a period of six financial years.

Details on the vote results will be available on the Company's website.

\*\*\*\*\*

### **About Abivax ([www.abivax.com](http://www.abivax.com))**

Abivax is a Phase 3 clinical stage biotechnology company, focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases. Abivax, founded by Truffle Capital, is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). Based in Paris and Montpellier, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of ulcerative colitis. More information on the company is available at [www.abivax.com](http://www.abivax.com). Follow us on Twitter [@ABIVAX\\_](https://twitter.com/ABIVAX_).

### **Contacts**

#### **Abivax**

##### **Communications**

Regina Jehle

[regina.jehle@abivax.com](mailto:regina.jehle@abivax.com)

+33 6 24 50 69 63

#### **Investors**

##### **LifeSci Advisors**

Ligia Vela-Reid

[lvela-reid@lifesciadvisors.com](mailto:lvela-reid@lifesciadvisors.com)

+44 7413 825310

#### **Press Relations & Investors Europe**

##### **MC Services AG**

Anne Hennecke

[anne.hennecke@mc-services.eu](mailto:anne.hennecke@mc-services.eu)

+49 211 529 252 22

#### **Public Relations France**

##### **Actifin**

Ghislaine Gasparetto

[ggasparetto@actifin.fr](mailto:ggasparetto@actifin.fr)

+33 6 21 10 49 24

#### **Public Relations France**

##### **Primatice**

Thomas Roborel de Climens

[thomasdeclimens@primatice.com](mailto:thomasdeclimens@primatice.com)

**+33 6 78 12 97 95**

#### **Public Relations USA**

##### **Rooney Partners LLC**

Jeanene Timberlake

[jtimberlake@rooneypartners.com](mailto:jtimberlake@rooneypartners.com)

+1 646 770 8858